icon-folder.gif   Conference Reports for NATAP  
 
  International Symposium on Viral Hepatitis and Liver Disease
March 20th - 24th 2009
Washington, DC
Back grey_arrow_rt.gif
 
 
 
Long-term Entecavir Therapy Results in Reversal of Fibrosis/Cirrhosis and Continued Histologic Improvement in Patients with HBeAg(+) and (-) Chronic Hepatitis B: Results from Studies ETV-022, -027 and -901
 
 
  Reported by Jules Levin
13th ISVHLD Wash Dc March 20-24 2009
 
Y-F Liaw1, T-T Chang2, S-S Wu3, ER Schiff4, K-H Han5, C-L Lai6, R Safadi7, SS Lee8, W Halota9, ZD Goodman10, H Zhang11, R Hindes11, U Iloeje11, S Beebe11 and B Kreter12 1. Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan; 2. National Cheng Kung University Medical College, Tainan, Taiwan; 3. Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; 4. University of Miami Hospital & Clinics, Miami, FL, USA; 5. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; 6. Department of Medicine, Queen Mary's Hospital, University of Hong Kong, Hong Kong, China; 7. Division of Medicine, Hadassah Medical Center, Jerusalem, Israel; 8. Liver Unit, University of Calgary, Calgary, AB, Canada; 9. Klinika Chorob Zakaznych AM, Bydgoszcz, Poland; 10. Armed Forces Institute of Pathology, Washington, WA, USA; 11. Research & Development, Bristol-Myers Squibb Company, Wallingford, CT, USA; 12. Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA

regressionCon-1.gif

ULN-2.gif

Momm-3.gif

longSub-4.gif

liver-5.gif

allLoss-6.gif

ETV-7.gif

inThe-8.gif

LiverHis-9.gif

HAI-10.gif

Ishak-11.gif

AndEnd-12.gif

flare-13.gif